NEW YORK (GenomeWeb News) – Gen-Probe has made a bid to buy the Belgian molecular diagnostics company Innogenetics for €215 million ($334 million) in cash, or €6.10 a share, besting an April offer of €5.75 a share from drug maker Solvay.
 
The offer is roughly 4.3 times Innogenetics’ diagnostic revenues of approximately €51 million in 2007.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

ScienceInsider reports that a new security policy at the US Food and Drug Administration may prevent foreign nationals from working there.

WBUR in Boston looks into Orig3n's genetic fitness assessments to find more research is needed.

Cleveland.com reports that getting a DNA profile removed from a law enforcement database can be tricky.

In PNAS this week: de novo mutations contribute to non-syndromic craniosynostosis, fungal tree of life, and more.